Caligan Partners’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.2M | Hold |
1,435,130
| – | – | 2.92% | 9 |
|
|
2025
Q1 | $21.6M | Hold |
1,435,130
| – | – | 4.5% | 8 |
|
|
2024
Q4 | $23.6M | Hold |
1,435,130
| – | – | 5.98% | 5 |
|
|
2024
Q3 | $35.4M | Sell |
1,435,130
-863
| -0.1% | -$21.3K | 11.24% | 5 |
|
|
2024
Q2 | $36.4M | Hold |
1,435,993
| – | – | 8.5% | 3 |
|
|
2024
Q1 | $36.5M | Buy |
1,435,993
+354,633
| +33% | +$9.01M | 9.64% | 3 |
|
|
2023
Q4 | $24.5M | Hold |
1,081,360
| – | – | 8.26% | 3 |
|
|
2023
Q3 | $20.1M | Buy |
1,081,360
+361,069
| +50% | +$6.73M | 9.25% | 4 |
|
|
2023
Q2 | $18.7M | Buy |
720,291
+5,000
| +0.7% | +$130K | 10.52% | 2 |
|
|
2023
Q1 | $20.5M | Buy |
715,291
+123,616
| +21% | +$3.55M | 14.33% | 2 |
|
|
2022
Q4 | $17.5M | Buy |
+591,675
| New | +$17.5M | 14.58% | 2 |
|